References
- Bauer M S, Calabrese J, Dunner D L, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. American Journal of Psychiatry 1994; 151: 506–515
- Post R M, Frye M A, Denicoff K D, et al. Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar Disorder 2000; 2: 305–315
- Heuser I J, Schweiger U, Gotthardt U, et al. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. American Journal of Psychiatry 1996; 153: 93–99
- Schmider J, Lammers C, Gotthardt U, Dettling M, Holsboer F, Heuser I. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biology Psychiatry 1995; 38: 797–802
- Rybakowski J K, Twardowska K. The dexamethasone/ corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. Journal of Psychiatric Research 1999; 33: 363–370
- Watson S, Gallagher P, Ritchie J C, Ferrier I N, Young A H. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry 2004; 184: 496–502
- Zobel A W, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. Journal of Psychiatric Research 2001; 35: 83–94
- Seifritz E, Muller M, Hatzinger M, et al. State independent dysregulation of the HPA system in a patient with rapid cycling: longditudinal evaluation of DEX/hCRH test status and comparison with a non-rapid cycling major depressive control group. Depression 1995; 3: 204–208
- Greden J F, DeVigne J P, Albala A A, et al. Serial dexamethasone suppression tests among rapidly cycling bipolar patients. Biology Psychiatry 1982; 17: 455–462
- Joyce P R, Donald R A, Elder P A. Individual differences in plasma cortisol changes during mania and depression. Journal of Affective Disorders 1987; 12: 1–5
- Shimizu E, Kodama K, Sakamoto T, et al. Recovery from neuroendocrinological abnormalities and frontal hypoperfusion after remission in a case with rapid cycling bipolar disorder. Psychiatry and Clinical Neurosciences 1997; 51: 207–212
- Thompson J M, Ferrier I N, Hughes J H, Gray J M, Young A H. Neuropsychological function in a cohort of bipolar patients prospectively verified as euthymic. Acta Neuropsychiatrica 2000; 12: 170
- McQuade R, Young A H. Future therapeutic targets in mood disorders: the glucocorticoid receptor. British Journal of Psychiatry 2000; 177: 390–395
- Belanoff J K, Rothschild A J, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biology Psychiatry 2002; 52: 386–392
- Hoyberg O J, Wik G, Mehtonen O P, Peeters B WMM, Sennef C. Org 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: first clinical results. International Journal of Neuropsychopharmocology 2002; 5(Suppl. 1)S148
- Young A H, Gallagher P, Watson S, Del-Estal D, Owen B M, Nicol Ferrier I. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; 29: 1538–1545
- Bschor T, Adli M, Baethge C., et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 2002; 27: 470–478